

## **Product datasheet**

# anti-AAV5 (intact particle) mouse monoclonal, ADK5a, lyophilized, purified, sample

#### Short overview

 Cat. No.
 610148S

 Quantity
 10 μg

Concentration 50 μg/ml after reconstitution with 200 μl PBS

## **Product description**

Host Mouse
Antibody Type Monoclonal
Isotype IgG2a kappa
Clone ADK5a
Immunogen AAV5 capsids

Formulation Lyophilized; reconstitute in 200 μl sterile PBS

**Binding affinity** KD value (AAV5) = 4.9E-11 M **Synomym** Adeno-associated Virus 5, AAV-5

**Conjugate** Unconjugated

**Purification** Affinity chromatography

**Storage before** 2-8°C until indicated expiry date

reconstitution

Storage after Up to 3 months at 2-8°C; long term storage in aliquots at -20°C; avoid freeze/thaw cycles

reconstitution

Intended use Research use only

Application Affinity chromatography, Dot blot, ELISA, ICC/IF, IP, Neutralization assay

Reactivity AAV5

No reactivity AAV1, AAV11, AAV12, AAV2, AAV3, AAV4, AAV6, AAV7, AAV8, AAV9, AAVDJ, AAVrh10,

AAVrh74

## **Applications**

Affinity Chromatography Assay dependent

Dot Blot 1:500 (0.1 μg/ml; non-denaturing conditions)

**ELISA** Assay dependent

Immunocytochemistry (ICC) 1:20
Immunoprecipitation (IP) 1:5

**Neutralization Assay** EC50 ~7 ng/ml (AAV5) - assay dependent


#### Background

For characterization of different stages of infection and very useful for the analysis of the AAV5 assembly process. ADK5a specifically reacts with PROGEN Biotechnik GmbH | Maaßstraße 30 | D-69123 Heidelberg

intact adeno-associated virus 5 particles, empty and full capsids. Recognizes a conformational epitope of assembled capsids, not present in denatured capsid proteins and native but unassembled capsid proteins. The antibody cannot be used for immunoblotting. The antibody is usefull for neutralizing experiments.

Limited Use Label License: Research Use OnlyProduct is exclusively licensed to PROGEN Biotechnik GmbH. The use of these products for the development, manufacturing and sale of secondary products/derivatives which are based on the purchased products and/or which include the purchased product require a royalty based sub-license agreement.

### **Product images**



Neutralization of AAV5 with mouse monoclonal AAV5 antibody clone ADK5a (A) and mouse monoclonal AAV5 antibody clone ADK5b (B) by using AAV5-NanoLuc® viral particles from Promega. (A) anti-AAV5 (intact particle) mouse monoclonal, ADK5a (Cat. No. 610148) or (B) anti-AAV5 (intact particle) mouse monoclonal, ADK5b (Cat. No. 610149) were preincubated with AAV5-NanoLuc® viral particles for 30 min at RT at 300 rpm (antibody concentrations 0.2-3,000 ng/ml). HEK293 cells (100 µl) were plated at 200,000 cells/ml in DMEM + 1% FCS. Virus-antibody-mix (20 µl) was added to the cells and incubated for 16-24 h at 37°C. Extracellular NanoLuc Inhibitor and Nano-Glo® Live Cell Assay System (Promega) was added to the wells and incubated for 5 min at RT at 300 rpm. Luminescence was measured using an ID5-Reader and plotted with Softmax Pro 7.1 software to determine the EC50 values.


Serotype	Clone	Contact residues	Footprint residues	*VR
AAV5	ADK5a	244 N, 246 Q, 248-RE <u>IKSGSVD-256, 263 Y</u> 377 E, 378 N 453 L, 456 R 532 Q, <b>533 P</b> , 535-NPGTTVPSATYL-543, 546 N 653 V, 654 P, 656 S 697 Q, 698 F, 704-DSTGEYR-710	218, 240- <u>250-258, 261, 263, 267, <b>279</b></u> 331, <b>350</b> , 355- <b>359</b> -360, 364, 365, <u>377, 378</u> , 395 429-432, 437, <u>450, 451, 453-456</u> , 458, 459 <u>530-533-543, 545-548</u> 639, 641, <u>642, 648-<b>650</b>, <b>651</b>, 653-656-658, 660-662, <u>697-700, 704-712</u></u>	I III IV VII HI loop IX
	ADK5b	248 R 346-VQDS-319 443 N 530-NSQ5PAN-535, 540-ATYL-543, 545 G, 546 N 697 Q, 704 D, 706 T, 708-EYR-710	241-248 313- <u>315-319</u> , 321, 323, 355, 356, 358- <b>359-361</b> , <b>362</b> 440-443, 446-449 530- <b>533</b> -548 645- <b>650</b> , <b>651</b> , 653-656-661 697, 698, 704-712	II IV VII HI loop IX

Tseng et al. Adeno-Associated Virus Serotype 1 (AAV1)- and AAV5-Antibody Complex Structures Reveal Evolutionary Commonalities in Parvovirus Antigenic Reactivity. Journal of Virology (2015)

In the publication cited below multiple contact sites and footprint residues for ADK5a and ADK5b have been identified, that are very likely to be part of the binding site. The amino acids of each binding site are located in different parts of the protein chains and are recognized as the epitope of the antibody only in the assembled capsid where they are in close proximity to each other and in the correct conformation.

Tseng et al. Adeno-Associated Virus Serotyp 1 (AAV1)- and AAV5-Antibody Complex Structures Reveal Evolutionary Commonalities in PArvovirus Antigenic Reactivity. J. Virol. 89:1794-1808 (2015).

<sup>\*</sup>The residues in the VR are underlined. Those involved in AAV5 receptor binding are bold and italicized.



Dot blot analysis of native AAV1-AAV9, AAVrh10, AAVDJ capsids (1E+09-1E+10 capsids) and denatured AAV5 capsids (1E+09-1E+10 capsids, denatured at 95°C for 10 min in sample buffer). The nitrocellulose membrane was blocked with 5% dry milk in PBST (PBS + 0.1% Tween 20) for 1 h at RT. The primary antibody anti-AAV5 (intact particle) mouse monoclonal, ADK5a (Cat. No. 610148) was diluted in blocking buffer (antibody concentration 100 ng/ml) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using PierceTM ECL Western Blotting Substrate.

# References

Publication	Species	Application
Ohba K. et al. Adeno-associated virus vector system controlling capsid expression improves viral quantity and quality., iScience, 26, 106487, (2023).	AAV5	IP
Emmanuel, S. N., Mietzsch, M., Tseng, Y. S., Smith, J. K. & Agbandje-Mckenna, M. Parvovirus Capsid-Antibody Complex Structures Reveal Conservation of Antigenic Epitopes across the Family. Viral Immunol. 34, 3–17 (2021).	AAV5	binding region
Baatartsogt, N. et al. A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid. Mol. Ther Methods Clin. Dev. 22, 162–171 (2021).	AAV5	Neutralization
Silveria, M. A., Large, E. E., Zane, G. M., White, T. A. & Chapman, M. S. The structure of an aav5-aavr complex at 2.5 Ã resolution: Implications for cellular entry and immune neutralization of aav gene therapy vectors. Viruses 12, (2020).	AAV5	neutralization
Jose, A. et al. High-Resolution Structural Characterization of a New Adeno-associated Virus Serotype 5 Antibody Epitope toward Engineering Antibody-Resistant Recombinant Gene Delivery Vectors. J. Virol. 93, 1394–1412 (2019).	AAV5	сгуоЕМ

2024 April 25 / Version: 610148S/DS-291123lim | Page 4